1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Cognition Disorders

1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with Cognition Disorders in 4 studies

Research

Studies (4)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (25.00)	18.2507
2000's	2 (50.00)	29.6817
2010's	1 (25.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bennett, SA; Figeys, D; Herrmann, N; Lanctôt, KL; Mazereeuw, G; Oh, PI; Xu, H	1
Clayette, P; Dash, PK; Dong, CZ; Dou, H; Eggert, D; Gelbard, HA; Gendelman, HE; Gorantla, S; Heymans, F; Poluektova, L; Serradji, N	1
Browne, SM; Halligan, PW; Taggart, DP; Wade, DT	1
Epstein, LG; Kieburtz, K; Marder, K; McArthur, JC; McDermott, MP; Sacktor, N; Schifitto, G; Small, S	1

Trials

2 trial(s) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Cognition Disorders

Article	Year
Neuroprotection during cardiac surgery: a randomised trial of a platelet activating factor antagonist. Heart (British Cardiac Society), 2003, Volume: 89, Issue:8 Topics: Cognition Disorders; Coronary Artery Bypass; Double-Blind Method; Female; Humans; Imidazoles; Leucine; Male; Middle Aged; Neuroprotective Agents; Neuropsychological Tests; Platelet Activating Factor	2003
Randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment. Neurological AIDS Research Consortium. Neurology, 1999, Jul-22, Volume: 53, Issue:2 Topics: Adult; Cognition Disorders; Double-Blind Method; Female; HIV; Humans; Imidazoles; Leucine; Male; Middle Aged; Neuropsychological Tests; Platelet Activating Factor	1999

Other Studies

2 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Cognition Disorders

Article	Year
Platelet-activating factors are associated with cognitive deficits in depressed coronary artery disease patients: a hypothesis-generating study. Journal of neuroinflammation, 2014, Jul-04, Volume: 11 Topics: Aged; Chromatography, High Pressure Liquid; Cognition Disorders; Coronary Artery Disease; Cross-Sectional Studies; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Platelet Activating Factor; Spectrometry, Mass, Electrospray Ionization; Statistics as Topic	2014
Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders. Journal of neuroimmunology, 2009, Aug-18, Volume: 213, Issue:1-2 Topics: AIDS Dementia Complex; Animals; Anti-Inflammatory Agents; Brain; Cell Death; Cells, Cultured; Cognition Disorders; Disease Models, Animal; Focal Adhesion Kinase 2; Giant Cells; Gliosis; Humans; Immunologic Factors; Inflammation Mediators; Male; Mice; Mice, SCID; Microglia; Monocytes; NF-kappa B; Piperazines; Platelet Activating Factor	2009

Article

Year

Platelet-activating factors are associated with cognitive deficits in depressed coronary artery disease patients: a hypothesis-generating study.

Journal of neuroinflammation, 2014, Jul-04, Volume: 11

Topics: Aged; Chromatography, High Pressure Liquid; Cognition Disorders; Coronary Artery Disease; Cross-Sectional Studies; Depressive Disorder, Major; Female; Humans; Male; Middle Aged; Neuropsychological Tests; Platelet Activating Factor; Spectrometry, Mass, Electrospray Ionization; Statistics as Topic

2014

Development of a platelet-activating factor antagonist for HIV-1 associated neurocognitive disorders.

Journal of neuroimmunology, 2009, Aug-18, Volume: 213, Issue:1-2

Topics: AIDS Dementia Complex; Animals; Anti-Inflammatory Agents; Brain; Cell Death; Cells, Cultured; Cognition Disorders; Disease Models, Animal; Focal Adhesion Kinase 2; Giant Cells; Gliosis; Humans; Immunologic Factors; Inflammation Mediators; Male; Mice; Mice, SCID; Microglia; Monocytes; NF-kappa B; Piperazines; Platelet Activating Factor

2009